Burkhard Blank

Plus aucun poste en cours Fortune : 2 M $ au 31/05/2026

Profil

Burkhard Blank formerly worked at Laurantis Pharma Oy, as Chief Executive Officer from 2013 to 2014, RIEMSER Pharma GmbH, as Director, Acorda Therapeutics, Inc., as Head-Drug Safety, Acorda Therapeutics, Inc., as Chief Medical Officer, Head-Research & Development from 2016 to 2021, Mersana Therapeutics, Inc., as Head-Clinical Development & Regulatory Affairs, MannKind Corp., as Chief Medical Officer, EVP-Research & Development from 2023 to 2025, Altus Pharmaceuticals, Inc., as Chief Medical Officer & Executive Vice President from 2006 to 2009, Boehringer Ingelheim Pharmaceuticals, Inc., as SVP-Medicine & Drug Regulatory Affairs from 2001 to 2006, Pharnext SA, as Chief Medical Officer, Head-Research & Development, and Herantis Pharma Oyj, as Chief Medical Officer.
Dr. Blank received his doctorate degree from Philipps University of Marburg.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
MANNKIND CORPORATION 0,15%	15/07/2025	460 791 ( 0,15% )	2 M $	31/05/2026

Anciens postes connus de Burkhard Blank

Sociétés	Poste	Fin
MANNKIND CORPORATION	Directeur Technique/Scientifique/R&D	14/05/2025
ACORDA THERAPEUTICS, INC.	Directeur Technique/Scientifique/R&D	01/12/2021
Laurantis Pharma Oy	Directeur Général	01/05/2014
Altus Pharmaceuticals, Inc.	Directeur Technique/Scientifique/R&D	27/03/2009
Boehringer Ingelheim Pharmaceuticals, Inc.	Corporate Officer/Principal	01/06/2006